PH12016501756B1 - Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms - Google Patents

Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

Info

Publication number
PH12016501756B1
PH12016501756B1 PH12016501756A PH12016501756A PH12016501756B1 PH 12016501756 B1 PH12016501756 B1 PH 12016501756B1 PH 12016501756 A PH12016501756 A PH 12016501756A PH 12016501756 A PH12016501756 A PH 12016501756A PH 12016501756 B1 PH12016501756 B1 PH 12016501756B1
Authority
PH
Philippines
Prior art keywords
ondansetron
nausea
vomiting
treating
amount
Prior art date
Application number
PH12016501756A
Other languages
English (en)
Other versions
PH12016501756A1 (en
Inventor
Reza Fathi
Gilead Raday
Guy Goldberg
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54067752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501756(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of PH12016501756A1 publication Critical patent/PH12016501756A1/en
Publication of PH12016501756B1 publication Critical patent/PH12016501756B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12016501756A 2014-03-11 2016-09-07 Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms PH12016501756B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461951092P 2014-03-11 2014-03-11
US201461951074P 2014-03-11 2014-03-11
US201461951112P 2014-03-11 2014-03-11
US201462040136P 2014-08-21 2014-08-21
PCT/IB2015/000997 WO2015136377A2 (en) 2014-03-11 2015-03-11 Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

Publications (2)

Publication Number Publication Date
PH12016501756A1 PH12016501756A1 (en) 2016-11-07
PH12016501756B1 true PH12016501756B1 (en) 2016-11-07

Family

ID=54067752

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501756A PH12016501756B1 (en) 2014-03-11 2016-09-07 Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

Country Status (17)

Country Link
US (3) US9675588B2 (cg-RX-API-DMAC7.html)
EP (1) EP3116500B1 (cg-RX-API-DMAC7.html)
JP (1) JP6461186B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160132057A (cg-RX-API-DMAC7.html)
CN (1) CN106456611B (cg-RX-API-DMAC7.html)
AU (1) AU2015228545B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016020877B1 (cg-RX-API-DMAC7.html)
CA (1) CA2941829C (cg-RX-API-DMAC7.html)
CL (1) CL2016002251A1 (cg-RX-API-DMAC7.html)
IL (1) IL247698B (cg-RX-API-DMAC7.html)
MX (1) MX373002B (cg-RX-API-DMAC7.html)
PH (1) PH12016501756B1 (cg-RX-API-DMAC7.html)
RU (1) RU2706708C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201607511WA (cg-RX-API-DMAC7.html)
UA (1) UA121209C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015136377A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606276B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180014778A (ko) 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
CA3051614A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
JP7315383B2 (ja) * 2019-06-27 2023-07-26 株式会社Ｓｃｒｅｅｎホールディングス インクジェット用水性組成物及び固体製剤
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE60019334T2 (de) 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
PL1683526T3 (pl) * 2003-11-14 2012-09-28 Senju Pharma Co Preparat wodnego roztworu zawierający antybiotyk aminoglikozydowy i bromfenak
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
EP1976491B1 (en) 2006-01-27 2014-12-17 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
US20070190141A1 (en) 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
BRPI0621996B8 (pt) * 2006-08-18 2022-07-05 Evonik Roehm Gmbh preparação farmacêutica compreendendo um núcleo com um ingrediente ativo e com um ácido orgânico e/ou com o sal de um ácido orgânico, e um revestimento que envolve o núcleo e que compreende um ou mais copolímeros de (met)acrilato, e seu uso.
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004439A (es) 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
JP2010514679A (ja) 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20100196291A1 (en) 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110108058A1 (en) * 2009-11-11 2011-05-12 Axcelis Technologies, Inc. Method and apparatus for cleaning residue from an ion source component
AU2010343147A1 (en) 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
KR102270521B1 (ko) 2013-03-14 2021-06-30 레드힐 바이오파마 엘티디 구토억제 서방형 고체 제형

Also Published As

Publication number Publication date
EP3116500B1 (en) 2023-09-13
AU2015228545B2 (en) 2020-03-12
ZA201606276B (en) 2019-04-24
CN106456611A (zh) 2017-02-22
US20150258029A1 (en) 2015-09-17
CA2941829A1 (en) 2015-09-17
EP3116500A2 (en) 2017-01-18
CA2941829C (en) 2021-11-02
MX373002B (es) 2020-04-30
JP6461186B2 (ja) 2019-01-30
CN106456611B (zh) 2021-07-20
BR112016020877A8 (pt) 2021-07-20
BR112016020877B1 (pt) 2022-11-29
IL247698B (en) 2020-08-31
RU2016139474A (ru) 2018-04-11
CL2016002251A1 (es) 2017-11-03
WO2015136377A2 (en) 2015-09-17
RU2016139474A3 (cg-RX-API-DMAC7.html) 2018-10-26
KR20160132057A (ko) 2016-11-16
SG11201607511WA (en) 2016-10-28
MX2016011734A (es) 2017-02-13
AU2015228545A1 (en) 2016-09-22
US20200253933A1 (en) 2020-08-13
BR112016020877A2 (pt) 2017-08-15
US20170258768A1 (en) 2017-09-14
UA121209C2 (uk) 2020-04-27
US9675588B2 (en) 2017-06-13
RU2706708C2 (ru) 2019-11-20
EP3116500A4 (en) 2017-10-25
WO2015136377A3 (en) 2016-01-14
JP2017507966A (ja) 2017-03-23
US10668050B2 (en) 2020-06-02
PH12016501756A1 (en) 2016-11-07
IL247698A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
EP4233889A3 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
UY31698A (es) Preparacion solida de desintegracion oral
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
PH12016501756A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
JP2016530291A5 (cg-RX-API-DMAC7.html)
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
NZ598171A (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
ZA202000028B (en) Use of vibegron to treat overactive bladder
JP2016535794A5 (ja) 急速崩壊性固体剤形
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
WO2016108507A3 (ko) 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX386908B (es) Formulacion de liberacion modificada de naproxeno sodico.
IN2013MU03428A (cg-RX-API-DMAC7.html)